1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is sponsored by National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Neurological Disorders and Stroke (NINDS).
This funding opportunity, part of the NIH HEAL Initiative, supports the development of non-addictive analgesic therapeutics for pain treatment, focusing on small molecules and biologics. It utilizes a UG3/UH3 phased award mechanism and may include clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93.
853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders 93. 395 -- Cancer Treatment Research 93. 846 -- Arthritis, Musculoskeletal and Skin Diseases Research 93.
279 -- Drug Use and Addiction Research Programs 93. 273 -- Alcohol Research Programs 93. 233 -- National Center on Sleep Disorders Research 93.
840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders 93. 839 -- Blood Diseases and Resources Research 93. 213 -- Research and Training in Complementary and Integrative Health 93.
837 -- Cardiovascular Diseases Research 93. 838 -- Lung Diseases Research 93. 865 -- Child Health and Human Development Extramural Research 93.
867 -- Vision Research Last Updated: June 16, 2026 View version history on Grants. gov The purpose of this Notice of Funding Opportunity (NOFO) is to support the preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for the treatment of pain.
The goal of the program is to accelerate the advancement of promising early-stage therapeutic candidates and facilitate their readiness for Phase II clinical trials. Applicants must have a promising small molecule or biologic lead candidate for optimization, a strong biological rationale for the proposed approach, and established assays to guide the optimization process. The scope...
of the program includes lead optimization, early-stage development activities, IND-enabling studies, development of pharmacodynamic and/or target engagement biomarkers, preparation and submission of an Investigational New Drug (IND) application, and Phase I clinical testing.
This is a milestone-driven, phased cooperative agreement program that involves active participation by NIH program staff in project planning and ongoing monitoring of research progress.
Private institutions of higher education Public and state institutions of higher education Independent school districts Federally recognized Native American tribal governments Public and Indian housing authorities Special district governments City or township governments Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations For-profit organizations other than small businesses Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. Grantor contact information National Institute of Neurological Disorders and Stroke (NINDS) File name Description Last updated RFA-NS-27-007-Full-Announcement. html RFA-NS-27-007-Full-Announcement.
html Jun 16, 2026 03:42 PM UTC Link to additional information Closing: February 20, 2029 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Eligible applicants include various research institutions and organizations. Confirm the full requirements in the official notice before applying.
Applications for HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) are due February 21, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is funded by National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Five NHLBI Catalyze Product Definition RFAs — HL-26-016 through HL-26-020 — carry an October 21, 2026 receipt date, budget caps of $300,000 to $400,000 per year, and roughly 8 new awards annually. The science is not the gate. An Accelerator Partner and a 0.25:1 non-federal cost match are, and both take longer to line up than the nine weeks you have left.
Read articleThe $46M FSHARP program is creating shelf-stable synthetic blood from freeze-dried components. A new SWiFT SBIR topic opened May 6 for autonomous field transfusion devices. What grant seekers in biomedical engineering need to know.
Read articleThe AIR program is ARPA-H's most ambitious bet yet: fully autonomous robots that perform stroke-saving thrombectomies without a human surgeon. Proposals are due March 18. A strategic guide for applicants.
Read article